BioDelivery Sciences stock has surged in the past month because investors realize the potential for Bunavail, its recently FDA approved treatment for opioid dependency, says the company's CEO Dr. Mark Sirgo. Sirgo says the ability of Bunavail to stick on the inside of the cheek, unlike products that need to be kept in place under the tongue until they dissolve, is evolutionary because it allows patients to talk, swallow and go about normal daily activities while the medication is being consistently absorbed. Sirgo says the product has peak sales potential of $250M and will hit the market in late 2014.

undefined

More from Video

Racing Legend Mario Andretti Has Great Advice for Retirees

Racing Legend Mario Andretti Has Great Advice for Retirees

Arianna Huffington on Burnout, Tech-Life Balance and Why Amazon's CEO Agrees

Arianna Huffington on Burnout, Tech-Life Balance and Why Amazon's CEO Agrees

Nucor Is Waiting to See if Steel Tariffs Will Be Implemented, Jim Cramer Says

Nucor Is Waiting to See if Steel Tariffs Will Be Implemented, Jim Cramer Says

Jim Cramer: Will Apple or Amazon Become the World's First Trillion Dollar Stock?

Jim Cramer: Will Apple or Amazon Become the World's First Trillion Dollar Stock?

Video: Jim Cramer on Apple, Amazon, Alphabet and Nucor

Video: Jim Cramer on Apple, Amazon, Alphabet and Nucor